A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).

Alan L HoNathan R FosterShyamprasad Deraje VasudevaNora KatabiCristina R AntonescuGary P FrenetteDavid G PfisterCharles ErlichmanGary K Schwartz

Published in: Cancer (2023)

MK-2206 failed to induce clinical responses in patients with incurable ACC. AKT inhibition may diminish MYB protein levels, although the effect was highly variable among patients. Novel approaches to target MYB in ACC are needed.

Keyphrases

transcription factor
signaling pathway
cell proliferation
open label
amino acid
randomized controlled trial
clinical trial
double blind